$UBX
Unity Biotechnology, Inc. Stock $ubx

$ubx Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000156459021014854 Filed on March 23, 2021

Income Statement

Concept	2020 Q4	2020 Q3	2020 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.220M	$6.530M	$6.320M
YoY Change	6.31%	14.76%	27.16%
% of Gross Profit
Research & Development	$13.09M	$18.83M	$16.12M
YoY Change	-28.12%	5.92%	-12.7%
% of Gross Profit
Depreciation & Amortization	$810.0K	$830.0K	$910.0K
YoY Change	9.46%	29.69%	42.19%
% of Gross Profit
Operating Expenses	$18.31M	$18.83M	$23.35M
YoY Change	-20.7%	-15.76%	-4.58%
Operating Profit	-$18.78M	-$24.64M	-$23.35M
YoY Change	-18.65%	10.24%	-4.58%
Interest Expense	-$690.0K	-$270.0K	$0.00
YoY Change	-209.52%	-135.71%	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$110.0K	-$2.637M	$4.342M
YoY Change	-102.48%	2254.46%	-4315.53%
Pretax Income	-$19.59M	-$27.55M	-$18.67M
YoY Change	8.65%	26.9%	-21.12%
Income Tax
% Of Pretax Income
Net Earnings	-$19.59M	-$27.55M	-$18.67M
YoY Change	8.65%	26.91%	-21.15%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.65	-$5.25	-$3.76
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2020 Q3	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$97.70M	$132.2M	$119.5M
YoY Change	-23.37%	16.99%	-6.64%
Cash & Equivalents	$17.81M	$48.58M	$39.59M
Short-Term Investments	$79.90M	$83.60M	$79.90M
Other Short-Term Assets	$3.200M	$3.500M	$4.000M
YoY Change	60.0%	59.09%	42.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$100.9M	$135.7M	$123.5M
YoY Change	-22.1%	7.78%	-12.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.63M	$37.80M	$39.10M
YoY Change	-24.1%	600.0%	591.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$17.90M	$0.00	$0.00
YoY Change	496.67%	-100.0%	-100.0%
Other Assets	$0.00	$1.400M	$598.0K
YoY Change	-100.0%	-15.0%	-63.51%
Total Long-Term Assets	$55.45M	$39.30M	$41.20M
YoY Change	155.14%	149.08%	222.29%
TOTAL ASSETS
Total Short-Term Assets	$100.9M	$135.7M	$123.5M
Total Long-Term Assets	$55.45M	$39.30M	$41.20M
Total Assets	$156.3M	$175.0M	$164.7M
YoY Change	3.37%	23.52%	6.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.558M	$4.300M	$3.952M
YoY Change	-50.67%	-6.07%	-26.56%
Accrued Expenses	$6.550M	$12.70M	$6.250M
YoY Change	31.13%	158.55%	29.13%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00
YoY Change
Total Short-Term Liabilities	$14.46M	$16.90M	$15.67M
YoY Change	-15.99%	18.18%	2.87%
LONG-TERM LIABILITIES
Long-Term Debt	$24.51M	$24.31M	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$35.60M	$36.80M
YoY Change	-100.0%	182.54%	525614.29%
Total Long-Term Liabilities	$24.51M	$24.31M	$36.80M
YoY Change		92.96%	525614.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.46M	$16.90M	$15.67M
Total Long-Term Liabilities	$24.51M	$24.31M	$36.80M
Total Liabilities	$73.44M	$76.87M	$52.44M
YoY Change	140.67%	185.12%	93.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$339.3M	-$319.7M	-$292.2M
YoY Change	38.23%		42.04%
Common Stock	$422.4M	$418.0M	$404.8M
YoY Change	15.19%		21.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$82.88M	$98.10M	$112.3M
YoY Change
Total Liabilities & Shareholders Equity	$156.3M	$175.0M	$164.7M
YoY Change	3.37%	23.5%	6.8%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2020 Q2
OPERATING ACTIVITIES
Net Income	-$19.59M	-$27.55M	-$18.67M
YoY Change	8.65%	26.91%	-21.15%
Depreciation, Depletion And Amortization	$810.0K	$830.0K	$910.0K
YoY Change	9.46%	29.69%	42.19%
Cash From Operating Activities	-$16.71M	-$17.26M	-$19.29M
YoY Change	6.5%	2.55%	-0.05%
INVESTING ACTIVITIES
Capital Expenditures	$180.0K	$90.00K	$350.0K
YoY Change	-70.49%	-83.33%	52.17%
Acquisitions
YoY Change
Other Investing Activities	-$14.40M	-$6.510M	$12.65M
YoY Change	273.06%	-125.41%	68.44%
Cash From Investing Activities	-$14.58M	-$6.610M	$12.31M
YoY Change	225.45%	-126.35%	69.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	520.0K	32.86M	21.51M
YoY Change	-97.51%	507.39%	2344.32%
NET CHANGE
Cash From Operating Activities	-16.71M	-17.26M	-19.29M
Cash From Investing Activities	-14.58M	-6.610M	12.31M
Cash From Financing Activities	520.0K	32.86M	21.51M
Net Change In Cash	-30.77M	8.990M	14.53M
YoY Change	-4495.71%	-34.24%	-230.43%
FREE CASH FLOW
Cash From Operating Activities	-$16.71M	-$17.26M	-$19.29M
Capital Expenditures	$180.0K	$90.00K	$350.0K
Free Cash Flow	-$16.89M	-$17.35M	-$19.64M
YoY Change	3.62%	-0.12%	0.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
CY2020	dei	Trading Symbol TradingSymbol	UBX
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-2054000
CY2020	us-gaap	Restructuring And Related Activities Initiation Date RestructuringAndRelatedActivitiesInitiationDate	2020-09-30
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y6M
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.926
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.994
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.874
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0029
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0159
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.026
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.079
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.113
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.926
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0052
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0227
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.030
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1999000
CY2018	ubx	Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments	374000
CY2020	ubx	Change In Fair Value Of Contingent Consideration For License Agreements ChangeInFairValueOfContingentConsiderationForLicenseAgreements	-33000
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	2629000
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Operating Expenses OperatingExpenses	93930000
CY2019	us-gaap	Operating Expenses OperatingExpenses	89651000
CY2018	us-gaap	Operating Expenses OperatingExpenses	79465000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-89651000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-79465000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-82177000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	160693000
CY2019	ubx	Vesting Of Early Exercised Options VestingOfEarlyExercisedOptions	647000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10852000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-93844000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3449000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2663000
CY2020	ubx	Amortization Of Debt Issuance Costs AmortizationOfDebtIssuanceCosts	318000
CY2019	ubx	Amortization Of Debt Issuance Costs AmortizationOfDebtIssuanceCosts	0
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-93929000
CY2018	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2018	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0
CY2018	ubx	Accretion Of Tenant Improvement Allowance AccretionOfTenantImprovementAllowance	605000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1168000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	169000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-628000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	31000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2640000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-227000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-517000
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2114000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-857000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-587000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43624807
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28269907
CY2018	ubx	Vesting Of Early Exercised Options VestingOfEarlyExercisedOptions	584000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9441000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	773000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	241000
CY2020	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	45000
CY2019	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	73000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27438000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22970000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38919000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15949000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38919000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	0
CY2018	ubx	Issuance Of Common Stock In Settlement Of Contingent Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentConsiderationMilestone	0
CY2018	ubx	Issuance Of Shares In Settlement Of Share Based Liability IssuanceOfSharesInSettlementOfShareBasedLiability	0
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	0
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37473000
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	84508000
CY2019Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	5507000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3167000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	100866000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	129487000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12627000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16636000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23509000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	17871000
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	3025000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1446000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1446000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	627000
CY2020Q4	us-gaap	Assets Assets	156319000
CY2019Q4	us-gaap	Assets Assets	151221000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2558000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5185000
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5355000
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	5905000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6550000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4995000
CY2020Q4	ubx	License Agreement Contingent Consideration Liability Current LicenseAgreementContingentConsiderationLiabilityCurrent	0
CY2019Q4	ubx	License Agreement Contingent Consideration Liability Current LicenseAgreementContingentConsiderationLiabilityCurrent	1131000
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	13298000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	24508000
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53253213
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53253213
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	156319000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47227065
CY2020Q4	ubx	Employee Promissory Notes For Purchase Of Common Stock EmployeePromissoryNotesForPurchaseOfCommonStock	0
CY2019Q4	ubx	Employee Promissory Notes For Purchase Of Common Stock EmployeePromissoryNotesForPurchaseOfCommonStock	418000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-245455000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	82880000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	120707000
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47227065
CY2020Q4	ubx	Related Party Promissory Notes For Purchase Of Common Stock RelatedPartyPromissoryNotesForPurchaseOfCommonStock	210000
CY2019Q4	ubx	Related Party Promissory Notes For Purchase Of Common Stock RelatedPartyPromissoryNotesForPurchaseOfCommonStock	210000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	90000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-339299000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	151221000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24025000
CY2019	ubx	Change In Fair Value Of Contingent Consideration For License Agreements ChangeInFairValueOfContingentConsiderationForLicenseAgreements	-1352000
CY2018	ubx	Change In Fair Value Of Contingent Consideration For License Agreements ChangeInFairValueOfContingentConsiderationForLicenseAgreements	4542000
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3312000
CY2020	ubx	Interest Expense Non Operating InterestExpenseNonOperating	1292000
CY2019	ubx	Interest Expense Non Operating InterestExpenseNonOperating	0
CY2018	ubx	Interest Expense Non Operating InterestExpenseNonOperating	0
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-93844000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-85000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	185000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-81992000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.84
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.88
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.70
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50864889
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-83113000
CY2018	ubx	Initial Public Offering Issuance Cost InitialPublicOfferingIssuanceCost	9149000
CY2018	ubx	Issuance Of Common Stock Upon Initial Public Offering IssuanceOfCommonStockUponInitialPublicOffering	75852000
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	233839000
CY2018	ubx	Stock Issued During Period Value Stock Options Early Exercised StockIssuedDuringPeriodValueStockOptionsEarlyExercised	1212000
CY2018	ubx	Stock Issued During Period Value Upon Exercise Of Warrants And Stock Options StockIssuedDuringPeriodValueUponExerciseOfWarrantsAndStockOptions	374000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000
CY2018	ubx	Receipt Of Promissory Note From Related Party To Purchase Common Stock ReceiptOfPromissoryNoteFromRelatedPartyToPurchaseCommonStock	390000
CY2018	ubx	Receipt Of Promissory Note From Employees To Purchase Common Stock ReceiptOfPromissoryNoteFromEmployeesToPurchaseCommonStock	400000
CY2018	ubx	Repayment Of Promissory Note From Related Party RepaymentOfPromissoryNoteFromRelatedParty	895000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	840000
CY2019	ubx	Common Stock Issued To Third Parties Value CommonStockIssuedToThirdPartiesValue	2995000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	586000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	185000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-82177000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	120707000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1510000
CY2020	ubx	Vesting Of Early Exercised Options VestingOfEarlyExercisedOptions	216000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13746000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7848000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	9441000
CY2020	ubx	Loss On Disposal Of Property And Equipment LossOnDisposalOfPropertyAndEquipment	0
CY2019	ubx	Loss On Disposal Of Property And Equipment LossOnDisposalOfPropertyAndEquipment	0
CY2020	ubx	Receipt Of Promissory Note From Related Party To Purchase Common Stock ReceiptOfPromissoryNoteFromRelatedPartyToPurchaseCommonStock	0
CY2019	ubx	Receipt Of Promissory Note From Related Party To Purchase Common Stock ReceiptOfPromissoryNoteFromRelatedPartyToPurchaseCommonStock	27000
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	100000
CY2020	ubx	Common Stock Issued To Third Parties For Milestone Payments Value CommonStockIssuedToThirdPartiesForMilestonePaymentsValue	2310000
CY2020	ubx	Repayment Of Promissory Note From Related Party From Purchase Of Common Stock RepaymentOfPromissoryNoteFromRelatedPartyFromPurchaseOfCommonStock	374000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	576000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-85000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-93844000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-76398000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2180000
CY2018	ubx	Amortization Of Debt Issuance Costs AmortizationOfDebtIssuanceCosts	0
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-256000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1151000
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	955000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	13813000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	10852000
CY2018	ubx	Loss On Disposal Of Property And Equipment LossOnDisposalOfPropertyAndEquipment	45000
CY2020	ubx	Common Stock Issued To Third Parties CommonStockIssuedToThirdParties	1211000
CY2019	ubx	Common Stock Issued To Third Parties CommonStockIssuedToThirdParties	965000
CY2018	ubx	Common Stock Issued To Third Parties CommonStockIssuedToThirdParties	0
CY2020	ubx	Non Cash Rent Expense NonCashRentExpense	1076000
CY2019	ubx	Non Cash Rent Expense NonCashRentExpense	0
CY2018	ubx	Non Cash Rent Expense NonCashRentExpense	0
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	2629000
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	502000
CY2019	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	4507000
CY2020	ubx	Accretion Of Tenant Improvement Allowance AccretionOfTenantImprovementAllowance	0
CY2019	ubx	Accretion Of Tenant Improvement Allowance AccretionOfTenantImprovementAllowance	1275000
CY2020	ubx	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-33000
CY2019	ubx	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-1352000
CY2018	ubx	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	4542000
CY2020	ubx	Increase Decrease In Contribution Receivable IncreaseDecreaseInContributionReceivable	0
CY2019	ubx	Increase Decrease In Contribution Receivable IncreaseDecreaseInContributionReceivable	0
CY2018	ubx	Increase Decrease In Contribution Receivable IncreaseDecreaseInContributionReceivable	-1382000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	842000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	604000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2228000
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1610000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1446000
CY2020	ubx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0
CY2019	ubx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	2461000
CY2018	ubx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-93000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78333000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-72421000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-56623000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	138486000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	119270000
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	204086000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	127915000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	188809000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	133644000
CY2020	ubx	Sale Of Strategic Investments SaleOfStrategicInvestments	6009000
CY2019	ubx	Sale Of Strategic Investments SaleOfStrategicInvestments	0
CY2018	ubx	Sale Of Strategic Investments SaleOfStrategicInvestments	0
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15949000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	0
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	13000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	565000
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	24550000
CY2020	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0
CY2019	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0
CY2018	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	500000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	646000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1586000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1264000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5208000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	67953000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-72206000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37270000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26085000
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	374000
CY2019	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0
CY2018	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	360000
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0
CY2019	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0
CY2018	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	59881000
CY2020	ubx	Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments	1510000
CY2019	ubx	Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments	840000
CY2020	ubx	Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan	576000
CY2019	ubx	Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan	586000
CY2018	ubx	Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan	0
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	79055000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3201000
CY2020	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	0
CY2019	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	0
CY2018	us-gaap	Proceeds From Repayments Of Secured Debt ProceedsFromRepaymentsOfSecuredDebt	895000
CY2018	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	74000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	63875000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	136930000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19666000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8101000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19253000
CY2020	ubx	Issuance Of Common Stock In Settlement Of Contingent Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentConsiderationMilestone	1098000
CY2019	ubx	Issuance Of Common Stock In Settlement Of Contingent Consideration Milestone IssuanceOfCommonStockInSettlementOfContingentConsiderationMilestone	0
CY2020	ubx	Issuance Of Shares In Settlement Of Share Based Liability IssuanceOfSharesInSettlementOfShareBasedLiability	100000
CY2019	ubx	Issuance Of Shares In Settlement Of Share Based Liability IssuanceOfSharesInSettlementOfShareBasedLiability	0
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	27714000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2018	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2020	ubx	Lessor Funded Lease Incentives Included In Property And Equipment LessorFundedLeaseIncentivesIncludedInPropertyAndEquipment	0
CY2019	ubx	Lessor Funded Lease Incentives Included In Property And Equipment LessorFundedLeaseIncentivesIncludedInPropertyAndEquipment	10651000
CY2018	ubx	Lessor Funded Lease Incentives Included In Property And Equipment LessorFundedLeaseIncentivesIncludedInPropertyAndEquipment	0
CY2020	ubx	Receipt Of Promissory Note For Purchase Of Common Stock ReceiptOfPromissoryNoteForPurchaseOfCommonStock	0
CY2019	ubx	Receipt Of Promissory Note For Purchase Of Common Stock ReceiptOfPromissoryNoteForPurchaseOfCommonStock	0
CY2018	ubx	Receipt Of Promissory Note For Purchase Of Common Stock ReceiptOfPromissoryNoteForPurchaseOfCommonStock	400000
CY2018	ubx	Receipt Of Promissory Note From Related Party To Purchase Common Stock ReceiptOfPromissoryNoteFromRelatedPartyToPurchaseCommonStock	390000
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-339300000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-93800000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78300000
CY2020Q4	ubx	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	115600000
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amount of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining the fair value of assets and liabilities, contingent consideration liability, the fair value of right-of-use assets and lease liabilities, and stock-based compensation. Actual results could differ from such estimates or assumptions. </p>
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17807000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37473000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15399000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1446000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1446000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	550000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19253000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38919000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15949000
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. Substantially all of the Company’s cash and cash equivalents and restricted cash is deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash deposits. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s investment policy limits investments in marketable securities to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, restricted cash and marketable securities and issuers of marketable securities to the extent recorded on the balance sheets. As of December 31, 2020, the Company had no off-balance sheet concentrations of credit risk. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on third-party suppliers for key raw materials used in its manufacturing processes and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate raw materials. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. To date, the Company’s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and results of operations, including ongoing and planned clinical studies. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. <span style="color:#000000;">The Company continues to monitor the impact the COVID-19 pandemic may have on the clinical development of its product candidates, including potential delays or modifications to its ongoing and planned studies</span><span style="color:#000000;font-family:Arial;">. </span></p>
CY2020	us-gaap	Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk	As of December 31, 2020, the Company had no off-balance sheet concentrations of credit risk.
CY2020Q4	ubx	Concentration Risk Credit Risk Off Balance Sheet Risk ConcentrationRiskCreditRiskOffBalanceSheetRisk	0
CY2020Q4	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P3Y
CY2020	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	2600000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	111449000
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	124368000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	92000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	124459000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	111443000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	9000
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2020	ubx	Compound Library And Option Agreement Execution Month And Year CompoundLibraryAndOptionAgreementExecutionMonthAndYear	2016-02
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22369000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22952000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9742000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6316000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12627000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16636000
CY2020	us-gaap	Depreciation Depreciation	3400000
CY2019	us-gaap	Depreciation Depreciation	2700000
CY2018	us-gaap	Depreciation Depreciation	2200000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	371000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	695000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6550000
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4995000
CY2019Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1849000
CY2020Q4	ubx	Liability Related To Early Exercise Shares LiabilityRelatedToEarlyExerciseShares	21000
CY2019Q4	ubx	Liability Related To Early Exercise Shares LiabilityRelatedToEarlyExerciseShares	237000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4520000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2020Q4	ubx	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	1638000
CY2019Q4	ubx	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	2214000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	4721000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	1168000
CY2020	ubx	Impairment Of Operating Lease Right Of Use Asset ImpairmentOfOperatingLeaseRightOfUseAsset	1409000
CY2020	us-gaap	Lease Cost LeaseCost	7298000
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	4500000
CY2018	us-gaap	Operating Lease Expense OperatingLeaseExpense	1800000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	5797000
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6653000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6283000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4810000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4964000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5123000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	22179000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	50012000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11024000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	38988000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4520000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	34468000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	3838000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	12272000
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	8890000
CY2020Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	25000000
CY2020Q4	ubx	Term Fee Due At Maturity Amount TermFeeDueAtMaturityAmount	1562000
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	26562000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	24508000
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000
CY2019Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	10000000
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53253213
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53253213
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47227065
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47227065
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	122000000
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	140000000
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	91739149
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	103283818
CY2020Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	33
CY2020Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.32
CY2020	us-gaap	Severance Costs1 SeveranceCosts1	1800000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2916320
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6906898
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.62
CY2020	ubx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Added In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAddedInPeriod	5587088
CY2020	ubx	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod	7887420
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4236256
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.37
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	308484
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.78
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	3654776
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3359198
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.04
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4270764
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7475472
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.88
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5261000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3925216
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.87
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4086000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	7475472
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.88
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5261000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1500000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5800000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1500000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.83
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.12
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.20
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4100000
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	7300000
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3200000
CY2020	ubx	Share Based Compensation Arrangement By Share Based Payment Number Of Shares Issued In Settlement Of Liability Award ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesIssuedInSettlementOfLiabilityAward	13550
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	200000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	57126000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40435000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5411000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3436000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9441000
CY2020	ubx	Share Based Compensation Arrangement By Share Based Payment Expense Related To Liability Award ShareBasedCompensationArrangementByShareBasedPaymentExpenseRelatedToLiabilityAward	100000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-93844000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-82177000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-76398000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50864889
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43624807
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28269907
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.84
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.88
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.70
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10700673
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7427297
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13813000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10852000
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6591409
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.022
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.009
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.009
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.009
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.007
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.005
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.003
CY2020	ubx	Effective Income Tax Rate Reconciliation Income Expense Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationIncomeExpenseTaxCreditsResearchAndDevelopment	0.022
CY2019	ubx	Effective Income Tax Rate Reconciliation Income Expense Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationIncomeExpenseTaxCreditsResearchAndDevelopment	-0.002
CY2018	ubx	Effective Income Tax Rate Reconciliation Income Expense Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationIncomeExpenseTaxCreditsResearchAndDevelopment	0.010
CY2020	ubx	Effective Income Tax Rate Reconciliation Reduction To State Net Operating Losses EffectiveIncomeTaxRateReconciliationReductionToStateNetOperatingLosses	0.001
CY2019	ubx	Effective Income Tax Rate Reconciliation Reduction To State Net Operating Losses EffectiveIncomeTaxRateReconciliationReductionToStateNetOperatingLosses	-0.039
CY2018	ubx	Effective Income Tax Rate Reconciliation Reduction To State Net Operating Losses EffectiveIncomeTaxRateReconciliationReductionToStateNetOperatingLosses	0
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	49781000
CY2020Q4	ubx	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	4946000
CY2019Q4	ubx	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	0
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1750000
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0
CY2020Q4	ubx	Deferred Tax Liabilities Unrealized Gains On Equity Investments DeferredTaxLiabilitiesUnrealizedGainsOnEquityInvestments	0
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	48834000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	22100000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11000000.0
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4326000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.235
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.133
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.231
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019Q4	ubx	Deferred Tax Liabilities Unrealized Gains On Equity Investments DeferredTaxLiabilitiesUnrealizedGainsOnEquityInvestments	947000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6696000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	947000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70950000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3514000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	1145000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	1232000
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1181000
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	241000
CY2020Q4	ubx	Deferred Tax Assets Tax Deferred Expense Contingent Consideration Liability DeferredTaxAssetsTaxDeferredExpenseContingentConsiderationLiability	0
CY2019Q4	ubx	Deferred Tax Assets Tax Deferred Expense Contingent Consideration Liability DeferredTaxAssetsTaxDeferredExpenseContingentConsiderationLiability	670000
CY2020Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	254000
CY2019Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	253000
CY2020Q4	ubx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	8203000
CY2019Q4	ubx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	0
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	77646000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9762000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3714000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	255000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6221000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2875000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	173000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7142000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9762000
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0
CY2019	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2020	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27156000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23349000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-24642000
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-18783000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-28038000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-18667000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-27552000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-19587000
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19737000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-24470000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22354000
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-23090000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-18767000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-23673000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-21710000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-18027000
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39

Files In Submission

Name	View Source	Status
0001564590-21-014854-index-headers.html	Edgar Link	pending
0001564590-21-014854-index.html	Edgar Link	pending
0001564590-21-014854.txt	Edgar Link	pending
0001564590-21-014854-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gmsn3wlcx05m000001.jpg	Edgar Link	pending
gmsn3wlcx05m000002.jpg	Edgar Link	pending
gmsn3wlcx05m000003.jpg	Edgar Link	pending
gmsn3wlcx05m000004.jpg	Edgar Link	pending
gmsn3wlcx05m000005.jpg	Edgar Link	pending
gmsn3wlcx05m000006.jpg	Edgar Link	pending
gmsn3wlcx05m000007.jpg	Edgar Link	pending
gmsn3wlcx05m000008.jpg	Edgar Link	pending
gmsn3wlcx05m000009.jpg	Edgar Link	pending
gmsn3wlcx05m000010.jpg	Edgar Link	pending
gmsn3wlcx05m000011.jpg	Edgar Link	pending
gmsn3wlcx05m000012.jpg	Edgar Link	pending
gmsn3wlcx05m000013.jpg	Edgar Link	pending
gmsn3wlcx05m000014.jpg	Edgar Link	pending
gmsn3wlcx05m000015.jpg	Edgar Link	pending
gmsn3wlcx05m000016.jpg	Edgar Link	pending
gmsn3wlcx05m000017.jpg	Edgar Link	pending
gmsn3wlcx05m000018.jpg	Edgar Link	pending
gmsn3wlcx05m000019.jpg	Edgar Link	pending
gmsn3wlcx05m000020.jpg	Edgar Link	pending
gyh40ym3xj0r000001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ubx-10k_20201231.htm	Edgar Link	pending
ubx-10k_20201231_htm.xml	Edgar Link	completed
ubx-20201231.xsd	Edgar Link	pending
ubx-20201231_cal.xml	Edgar Link	unprocessable
ubx-20201231_def.xml	Edgar Link	unprocessable
ubx-20201231_lab.xml	Edgar Link	unprocessable
ubx-20201231_pre.xml	Edgar Link	unprocessable
ubx-ex1014_239.htm	Edgar Link	pending
ubx-ex1015_238.htm	Edgar Link	pending
ubx-ex1017_237.htm	Edgar Link	pending
ubx-ex1018_236.htm	Edgar Link	pending
ubx-ex1019a_235.htm	Edgar Link	pending
ubx-ex1019b_234.htm	Edgar Link	pending
ubx-ex1019d_232.htm	Edgar Link	pending
ubx-ex1019e_233.htm	Edgar Link	pending
ubx-ex1019f_230.htm	Edgar Link	pending
ubx-ex1019g_231.htm	Edgar Link	pending
ubx-ex1020_228.htm	Edgar Link	pending
ubx-ex1021_229.htm	Edgar Link	pending
ubx-ex1038_72.htm	Edgar Link	pending
ubx-ex231_15.htm	Edgar Link	pending
ubx-ex311_14.htm	Edgar Link	pending
ubx-ex312_12.htm	Edgar Link	pending
ubx-ex321_13.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UBX
Unity Biotechnology, Inc. Stock $ubx

2020 Q4 Form 10-K Financial Statement

#000156459021014854 Filed on March 23, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UBX Unity Biotechnology, Inc. Stock $ubx

2020 Q4 Form 10-K Financial Statement

#000156459021014854 Filed on March 23, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UBX
Unity Biotechnology, Inc. Stock $ubx